Matters of the Heart: The Case of TNFα-Targeting Drugs

Table 1

Anti-TNFα Drugs and Approved Indications

Drug Class Structure Approved Indications
Infliximab (Remicade®) MoAb Chimeric (human-murine) recombinant anti-TNFα IgG1 graphic Rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Bechet disease
Adalimumab (Humira®) MoAb Fully human recombinant anti-TNFα IgG1 graphic Rheumatoid arthritis, juvenile idiopathic arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis.
Golimumab (Simponi®) MoAb Fully human recombinant anti-TNFα IgG1 graphic Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis.
Certolizumab-pegol (Cimzia®) Fab’ fragment Humanized PEGylated Fab’ fragment of anti-TNFα IgG1 graphic Rheumatoid arthritis, Crohn’s disease
Etanercept (Enbrel®) Fusion protein Fully human TNFR2 linked to IgG1 Fc graphic Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis.

  • MoAb, monoclonal antibody; Fab, fragment, antigen binding; TNFα, tumor necrosis factor α; TNFR2, TNFα receptor 2.

This Article

  1. MI April 2011 vol. 11 no. 2 79-87
  1. Full Text
  2. Full Text (PDF)

Current Issue

  1. April 2011, 11 (2)
  1. Current Issue
  1. Alert me to new issues of MI
Society Logo HighWire Press Logo CLOCKSS logo